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Abstract This studyreports ondata froma studyconductedinthe Federal Republicof Germanyexamining the qual-
ityof life (QoL) of patientswith chronic bronchitis (CB) andits acute exacerbations (AECB).Data from 320 patientswere
collected at AECB and subsequently during a stable phase (non-AECB) utilizing the St George’s Respiratory Question-
naire (SGRQ) and the Nottingham Health Pro¢le (NHP). As expected, the QoLof CB patientswas poor, even at non-
AECB, with patients reporting lower scores than patientswith other chronic conditions.Patients reported signi¢cantly
poorer QoL at AECB than at non-AECB. After adjusting for the severity of the underlying condition, poorer QoL at
AECBwas signi¢cantlyandindependently associatedwith older age, unemployment, increasing BMI, increasingnumber
ofpriorAECBs, andAnthonisenAECBgrade.Whileyounger subjectsreportedsigni¢cantlygreaterdeteriorationinQoL
at AECB, the factorsmostconsistently and independently associatedwith relative QoLdeterioration at AECBwere the
numberofpriorAECBs andexposureto airpollution athome.Inconclusion, this studyhighlights thedetrimentale¡ectof
CB, and in particular AECB, on QoL.The association between QoL andpatient reports of previous AECB number and
air pollution are consistentwithreports fromother studies.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1208, available online at http://www.idealibrary.comon
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Chronic bronchitis (CB) is de¢ned as a disease of the
airways persisting for at least 2 years, inwhich coughing
andexpectoration are involvedonmostdays of theweek
for at least 3 months of each year (1,2). Such simple CB
usually persists for years or even decades and is the ¢fth
most common disease in theworld.
CB is particularly common among men in
industrialized countries (2), with the prevalence rate in
the Federal Republic of Germany being estimated at10^
12% of the adult population (3).
The pathogenesis of CB is considered to be
multi-factorial, with there being evidence of association
with long-term exposure to tra⁄c emissions and otherReceived14 March 2001, accepted in revised form 21August 2001and
published online14 November 2001.
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such as smoking (4). Approximately 50% of smokers de-
velop symptoms of CB (8,9).
During the course of CB, su¡erers usually experience
episodes of increased symptoms such as breathlessness
(dyspnoea), sputum volume, and sputum purulence.These
episodes are referred to as acute exacerbations of CB
(AECB).Dyspnoea isregardedasbeingone of themostdis-
tressing and disabling symptoms of CB (10), with marked
e¡ects on the patient’s quality of life (11). The causes of
AECBs are multi-factorial, but bacterial infection is in-
volved in about half of cases (12,13).With theexception of
smoking,AECBs arewidelyregardedas thegreatest causa-
tive factor in CB progression (14).Moreover, since the
symptoms and frequency of AECBs generally increase dur-
ing the course of the condition there is a constant dete-
rioration in overall well-being (15). AECBs are rated
objectively in terms of symptom severity as one of three
types (16). However, recent classi¢cations have been pro-
posed which take into account the overall history of CB
(17) as well as its risk factors and treatment outcome (18).
40 RESPIRATORYMEDICINEMeasurement of quality of life (QoL), and in particular
its health-related components (HRQoL), is becoming
increasingly important in the clinical studies of many
chronic diseases. This recognizes the greater emphasis
now being placed on non-clinical aspects of treatment
(19). Thus, while QoL research in patients with chronic
lung disease has been underdeveloped for a long period
of time, the importance of assessing QoL in such
patients is becoming increasingly recognized. CB has a
decidedly negative impact onHRQoL since its symptoms
result in reduced energy and vitality, as well as anxiety,
depression, dependency, and loss of self-esteem. For
example, associations have been reported between CB
and depression (20), and with both di⁄culties in moving
and sleep disturbances (21).One study found associations
with psychological distress in relation to dependency on
medication, together with disruption of social and family
relationships (22). It has been observed that HRQoL de-
teriorates with increased severity of the CB as well as
with other factors such as the degree of bronchial
obstruction and colonisation of the lower airway, the
frequency and nature of AECBs, and the presence of risk
factors such as smoking, and inhalation of fumes, dust, or
other particulates in the workplace (23^27). In particu-
lar, HRQoL has been found to be signi¢cantly adversely
a¡ected during AECBs with increased anxieties about
breathlessness, fear of atmospheric pollution, and
embarrassment about coughing up phlegm in public
(22). Infective AECBs are reported to be associatedwith
a greater reduction in QoL (28). As a result, there is
growing recognition that the treatment and manage-
ment of CB and AECB should take QoL issues into ac-
count (23,27,29^34).
This paper reports on a multi-centre study carried
out in an ambulatory setting in Germany which was
aimed primarily at describing the costs associated with
CB and AECB. As such, data on a wide range of demo-
graphic, clinical, and risk factors were collected. The
results of the economic analyses have been published
elsewhere (35). Quality of life data, utilizing the St
George’s Hospital Respiratory Questionnaire (SGRQ)
and theNottinghamHealth Pro¢le (NHP),were also col-
lected.The SGRQ is a standardized self-completed ques-
tionnaire formeasuring impairedhealth andqualityof life
in chronic obstructive airways disease (COAD) (36,37).
The measure is designed to quantify the impact of
diseases of chronic air£ow limitation on health and
well-being and to be su⁄ciently sensitive to respond to
changes in disease severity. As such, it is a widely-used
QoL instrument in COAD (15,25,26,38,39). It contains
76 items divided into three domains entitled ‘Symptoms’
(the frequency and severity of respiratory symptoms),
‘Activity’ (activities that are limited by breathlessness),
and ‘Impact’ (the e¡ect of airways disease on social func-
tioning and psychological disturbance). A total SGRQ
score comprisingresponses to all items can alsobe calcu-lated. In terms of its psychometric properties, the SGRQ
has been shown to have good test^retest reliability, con-
struct validity, and sensitivity (36,37,40^42).The NHP is
also awidely-used generic healthmeasure previously ap-
plied in COAD studies (25,26,38,43^45), which has been
shown to be reliable (46,47), valid (45,47^49) and intern-
ally consistent (45).
Data in the present study were collected at the time
of an AECB and around 6 months later at a time of no
AECB.The aim of this paper is to compare and contrast
the HRQoL in individuals with CB during the stable
phase and its acute exacerbations so as to assess the im-
pact of AECBs on QoL. A secondary aim is to explore
the associationsbetweenQoL anddemographic, clinical,
and risk factors to determine which factors have the
greatest impact on HRQoL.
METHODS
On the basis of sample size calculations it was deter-
mined that around 780 patients would enable estimates
of CB and AECB costs to be given with su⁄cient preci-
sion, and that around 380 patients would be needed for
QoL comparisons. To allow for drop-outs, and taking
into account the number of CB patients typically seen
by doctors, the study was thus planned to be conducted
by 180 investigators who would each recruit ¢ve
patients, giving a sample of 900 patients. Assessment of
QoL was planned on half of these patients (i.e. 450).
Investigator recruitment was initiated by post in
August 1996, with recruitment of patients to occur be-
tween 1 and 31October 1996.The investigators were to
be either general practitioners or internists (CB gener-
ally being treated by these medical groups), and they
were to work in private practice representative of city
andrural areas.Therecruitment letterwas sent to a ran-
dom sample of 4500 general practitioners and internists
generated from a data bank of investigators.Those doc-
tors who expressed an interest in participating by re-
turning a reply postcard were telephoned to arrange an
initial personalmeeting.
The study had a two-stage design with initial recruit-
mentof patients during anAECB followedby subsequent
collection of data during a stable phase, approximately 6
months later (non-AECB). March/April 1997 was the
period planned for this assessment. The patients were
to complete the QoL questionnaires at both assessment
points.Datawas also collectedon every subsequentCB-
related visit to the doctor for 1 year following
recruitment; this data was intended for inclusion in the
overall costs analysis.
For the purposes of theQoL analysis, an approximate
50% random sample of patients was selected by
randomly selecting 50% of investigators whowere to be
provided with the relevant QoL documentation forms.
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tors following any subsequent AECB or during regular
visits to the doctor.Where appropriate, the patient was
reminded about the QoL forms by the investigator, who
also contacted the patient by telephone in April 1997.
Patients who had not returned to the doctor after the
¢rst exacerbationwere sent the questionnaires by post.
Patients to be recruited into the study were CB
su¡erers aged18 years or over who developed an infec-
tive AECB and presented to a study investigator during
the recruitment period. Although patients are unlikely
to have CB at 18, the rationale for conducting the study
was to recruit patients who were as representative as
possible of those diagnosed with CB in the community,
even though some diagnoses may be open to disagree-
ment.The de¢nition of CB was that used by theWHO:
‘chronicbronchitismustbe assumedwhen apatientcoughs
with expectoration (productive coughing) for at least 3
months per year over a period of 2 consecutive years’. Ex-
clusion criteria were treatment for CB since 1st October
1996 or the presence of bronchial asthma, bronchogenic
carcinoma or other pulmonarymalignancies.
At recruitment, patient-reported socio-demographic
and risk factors were collected including age, gender,
professional and social status, recognized disability,
weight and height, current tobacco smoking, allergies,
and exposure to atmospheric pollution at home an at
the workplace. The data on air pollution was collected
qualitatively (i.e. a patient response of either yes or no)
since it was not practicable physically to measure such
pollution.Clinical factors recorded (mostly by the physi-
cian) includedpast andpresentmedical history, including
the number of AECBs during the preceding 12 months
(patient recorded) and an assessment of the severity of
the basic pulmonary disease and the current AECB. In
this respect, the degree of severity of chronic bronchitis
was classi¢ed by the investigator as either ‘mild’, ‘moder-
ate’, or ‘severe’, solelyon thebasis of physician judgement,
and the following symptoms ofCBwerenoted: increased
di⁄culty in breathing/resting dyspnoea, cough (severity),
and expectoration (quantity and purulence).There were
no objectivemeasurements of pulmonary function since
such examinations arenotroutinelyperformedbygener-
al practitioners. AECBs were classi¢ed by the investiga-
tor as ‘mild’, ‘moderate’, or ‘severe’, solely on the basis of
physician judgement, and were further classi¢ed objec-
tively according to Anthonisen criteria where a type-1
exacerbation is the most severe and a type-3 the least
(16). The nature of any medications taken and details of
concomitant diseases were also recorded.
Statisticalmethods
Data were entered into Access 2.0 for Windows using
double data entry.Data were analysed using SPSS 9.0 forWindows.Data were initially examined for outliers and/
or any spurious ¢gures. Distributions were then exam-
ined using visual inspection of histograms together with
Kolmogorov^Smirnov tests to determine whether
transformation was necessary to achieve a Normal dis-
tribution. Since the QoL data were generally non-Nor-
mal, with transformation being unable to achieve
acceptable degrees of Normality, non-parametric tests
(Mann^Whitney U for comparing two independent
groups and Wilcoxon matched pairs signed ranks for
comparing paired data) were used, where possible, for
statistical analysis of the data. A kappa statistic (50) was
calculated to assess the degree of agreement between
the Anthonisen (16) and investigator ratings of AECB se-
verity. Regression analysis was used to explore the inde-
pendent e¡ects ofmultiple factors onQoL scores.These
analyses were performed in two main ways: ¢rst, to ex-
plore the independent e¡ects of individual factors adjust-
ing for the severity of the underlying condition, CB
severity was forced in at the ¢rst step followed by the
factor of interest; second, to explore the relative inde-
pendente¡ectof all factors, stepwisemultiple regression
was used, both with and without forcing in CB severity
at the ¢rst stage.For simplicity, only the results ofmulti-
ple regressionsadjusting forCB severity arepresented. In
all these regression analyses, continuous variables that
did not show a linear association with the dependent
variable were recorded into categories so not to violate
the linearity assumptions of regression.The data are pre-
sented using means and standard deviations for ease of
interpretation. While the signi¢cance level was set at
Po0?05 throughout, on account of multiple testing
those associations which are signi¢cant at Po0?01 are
consideredmost reliable.
RESULTS
Investigator recruitment
Two hundred and ¢fty-two of the doctors expressed
interest in participating by returning a reply postcard.
Appointments were arranged by telephone for initial
personal meetings, which were arranged with 226
doctors.Of these 226 doctors, 37 did not agree toparti-
cipate (largely because of lack of time or insu⁄cient re-
imbursement), leaving a total of 189 investigators. Of
these 189 investigators, 43 were withdrawn from the
study (16 because they had no patients meeting the
inclusion criteria,11because they had no time to conduct
the study,10 because they either had no interest in con-
tinuing the study or did not comply properly, and six for
reasons including investigator illness and loss of docu-
mentation forms). As a result,146 of the189 investigators
initially recruitedremained in the study.One investigator
was additionally recruitedduring the course of the study
by means of a change-of-doctor card. This investigator
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colleague until the study was completed. A total of 147
investigators therefore participated in the study. Of
these 147 investigators, 110 (75%) were general practi-
tioners, and 37 (25%) were internists.
Patient recruitment
Therecruitmentperiod initially setbetween1and 31Oc-
tober1996 was extended to 31March1997 since only 620
patients had been recruited during this period. In addi-
tion, the maximum number of patients to be recruited
by each investigator was increased to 10. By 31 March
1997, 804 patients had been recruited. Of these, 11
dropped outduring follow-up because either the patient
moved away (six patients) or the doctor declined to
participate further (¢ve patients). In addition, eight pa-
tients were excluded for reasons including recruitment
date after the speci¢ed period of recruitment or being
recruited while not having an AECB. For an additional
30 patients, data for only one doctor’s appointment was
recorded. The ¢nal sample size was therefore 755. Of
these patients, 320 completed either the SGRQ or the
NHP at the time of the AECB (236 completed the SGRQ
and 276 theNHP).These 320 patients form the sample to
be used in all the analyses reported in this paper.
Socio-demographic characteristics
Fifty-six per cent (n=179) of the 320 subjects were male
and theirmean (SD) agewas 60 (16) years, with a range of
18^92 years. The interquartile age range was 52^72
years-with only 15 (45%) of subjects aged less than 30
years. Only 29% (n=93) were employed, this re£ecting
the age distribution of the sample (77% of those not in
employment were retired).Thirteen per cent (n=40) of
the subjectshad a recognizeddisability as a resultof their
chronic bronchitis.
Potential risk factors
Thirty-¢ve per cent (n=111) of the subjects reported
being a current smoke at the time of their AECB, with
34% reporting smoking between1and10 cigarettes daily,
50% between 11 and 20, 12% between 21 and 30, and 4%
between 31 and 40. Thirteen per cent (n=43) reported
air pollution at home and 7% (n=20) exposure to air pol-
lution at work. Eleven per cent (n=36) reported some
form of allergy. All patients responding to the question
reported at least on concomitant illness at AECB, with
most patients reporting between one and three such ill-
ness (85%, n=220). The patients’ mean body mass index
[weight (kg)/height (m2)] was 25?8 with 43% (n=139)
being overweight, having a BMI of between 25 and 29?9,
and a further13% (n=41) being obese (BMI=30+) (51).Clinical factors
The majority of patients (64%, n=202) reported su¡er-
ing from between two and four AECBs over the past
year (range 0^12). In terms of the clinical symptoms of
CB, 73% (n=233) were diagnosed as having di⁄culty
breathing (73%, n=233), 75% (n=239) expectoration,
41% (n=131) purulent expectoration, and 85% (n=271)
increased cough. Most patients (73%, n=231) su¡ered
from a combination of two or three symptoms. Sixty-
four per cent (n=200) of patients were classi¢ed by the
investigators as having amoderate grade of CB,with12%
(n=37) being graded asmild and 25% (n=78) as severe.
The severity of the AECB, in terms of Anthonisen classi-
¢cation, was graded as mild (type 3) for 29% (n=87),
moderate (type 2) for 46% (n=139), and severe (type 1)
for 26% (n=78) of the patients. The physicians graded
the AECB as mild in 15% (n=46), moderate in 63%
(n=198), and severe in 23% (n=71) of the patients.Thus,
while physicians rated the majority of AECBs as moder-
ate, fewer than half were rated as such under Anthoni-
sen criteria, with poor agreementover that expectedby
chance (kappa=0?14,Po0?001).Ninety-sevenper centof
the patients (all who answered the question) reported
taking some form ofmedication, with the greatmajority
of patients (91%,n=284) taking from one to three di¡er-
ent types of medication. In terms of the type of medica-
tion taken, 69% (n=222) were taking expectorants, 57%
(n=182) antibiotics, 34% (n=110) mucolytics, 14%
(n=45) corticosteroids, 10% (n=32) anti-tussives and
7% (n=22) some other type ofmedication.
Quality of life at AECB andnon-AECB
Two hundred and seven patients completed the NHP,
and163 patients the SGRQ, at the two assessmentpoints
(AECB and non-AECB). One hundred and ¢fty-two
patients completed both questionnaires at both assess-
ments. To maximize sample size for each comparison,
QoL data is presented for subjects providing QoL data
on the speci¢c questionnaire domain at both assess-
ments. Table 1 shows the mean and SD QoL scores for
the NHP and SGRQ domains at each assessment,
together withmean (SD) change and its statistical signi¢-
cance (Wilcoxonmatched pairs signed ranks test).
In terms of both the SGRQ and theNHP, respondents
reported poorer quality of life at the time of the AECB
than at non-AECB.These di¡erences reached statistical
signi¢cance for all NHP domains, and for all SGRQ
domains with the exception of the Symptom domain,
scores for which were similar at the two assessment
points.The percentage deterioration in QoL at the time
of the AECB compared to the score at non-AECB was
greater in terms of the NHP (the deterioration ranging
from 38% to 53%) than the SGRQ (3^25%).
TABLE 1. Mean and SDNHPand SGRQ scores at AECB andnon-AECB, and their change
AECB Non-AECB
Domain n Mean SD Mean SD Mean (SD) change P-value (Wil-
coxontest)
NHP
Energy 200 60?41 37?91 42?48 39?48 17?94 (44?32) o0?001
Pain 194 13?75 23?37 9?77 19?82 3?99 (23?20) 0?006
Emotionalreactions 187 25?20 25?90 18?21 23?73 7?00 (25?78) o0?001
Sleep 197 35?96 32?10 25?45 29?62 10?51 (32?22) o0?001
Social isolation 199 16?81 25?79 10?99 22?21 5?82 (27?58) 0?003
Physicalmobility 195 26?50 25?64 18?47 23?90 8?02 (23?34) o0?001
SGRO
Symptoms 162 64?24 18?75 62?38 19?18 1?85 (18?62) 0?200
Activity 161 57?83 26?77 50?36 27?28 7?47 (24?11) o0?001
Impacts 161 40?12 20?78 32?03 21?99 8?09 (22?13) o0?001
Total 163 49?68 20?00 42?76 20?95 6?92 (19?26) o0?001
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non-AECBwith a general population sample
There are no German NHP population norms and so
U.K. population norms have been used for comparison
(55). These population norms are based on aggregated
data from ¢ve random samples representing a total of
6506 individuals. While these norms are available for
age, gender, and social class groups, the present study
did not collect data on social class.Table 2 thus presents
data within age and gender groups over all social
class groups. It is clear that within most age and gender
groups the QoL of CB patients at non-AECB is poor in
comparison with individuals in the general population
sample.The e¡ect of CB on QoL is particularly evident
in the NHP domains of energy, emotional reactions and
sleep.
ComparisonofNHPscores inCB patients at
non-AECBwith those of patientswith other
conditions
Table 3 showsmean (SD) NHP scores for: the CB patients
in the present study at non-AECB; a group of COPD
patients with co-morbid conditions (45); patients with
benign prostatic hypertrophy (BPH) (53); patients with
Parkinson’s disease (54); and a group of healthy elderly
individuals used as controls in the Parkinson’s disease
study (54). Since all the patients in the present study
reported some concomitant illness, the COPD patients
included in this comparison are the subset (n=58) of the
total group (n=170) with co-morbidity. Their mean age
(57 years, SD=8 years) is similar to that of the CBpatients in the present study (60 years, SD=16 years),
with the two groups reporting similar mean NHP do-
main scores.While the CB patients are younger than the
subjects in the three other comparison groups [mean
(SD) age 70 (8), 74 (8), 73 (8) years in the BPH, Parkinson’s
and control groups, respectively], they report poorer
NHP QoL than the patients in these other groups in
terms of the energy and emotional reactions domains.
Taking into account the lesser age of theCBpatients, this
emphasizes the detrimental e¡ect of CB on these QoL
domains even at a time of no AECB.
E¡ectof socio-demographic, riskandclinical
factors onQoL
Tables 4 and 5 show mean SGRQ scores at AECB and
non-AECB in terms of those factors having signi¢cant
relationship with QoL. Data are only shown for the
SGRQ because the relationships with the NHP are gen-
erally weaker and for a number of factors are not evi-
dent (to be discussed in a further report).
Socio-demographic factors
While there was little e¡ect of gender on QoL at both
AECB and non-AECB, increasing age was associated
with deteriorating QoL at both assessments (Tables 4
and 5).The relative deterioration at AECBwas, however,
greater (although non-signi¢cantly so) in younger indivi-
duals. For example, those aged o52 years reported a
mean (SD) deterioration in the total domain of 12?0
(16?5) compared with a deterioration of 1?01 (20?9) in
TABLE 2. MeanNHP scores at non-AECB byage group andgender.U.K. populationnorms across all social classes (52) are given inparentheses
20^34 yearsmale
(n= 15)
20^34 years
female (n= 15)
35^49 yearsmale
(n= 24)
35^49 years
female (n= 20)
50^65 yearsmale
(n= 65)
50^65 years
female (n= 50)
465 yearsmale
(n= 84)
465 years
female (n= 61)
Energy 16?32 (6?63) 25?87 (14?02) 31?63 (9?86) 26?77 (16?48) 37?69 (11?89) 44?00 (16?78) 47?36 (20?45) 51?77 (22?81)
Pain 0?58 (1?29) 4?14 (3?23) 6?63 (3?88) 0?80 (5?40) 4?89 (6?06) 10?56 (8?55) 11?45 (8?59) 19?04 (12?83)
Emotionalreactions 12?98 (6?06) 17?23 (11?48) 32?38 (9?87) 8?71 (12?35) 16?79 (8?61) 18?01 (11?63) 16?31 (9?44) 22?11 (11?56)
Sleep 13?78 (5?45) 12?21 (11?76) 42?93 (10?34) 12?09 (14?27) 24?06 (12?84) 27?73 (20?57) 20?89 (21?72) 32?38 (25?73)
Social isolation 18?40 (5?28) 13?56 (5?49) 8?16 (4?60) 1?57 (5?44) 8?70 (4?44) 6?59 (6?27) 12?02 (6?55) 18?48 (8?64)
Physicalmobility 11?30 (1?15) 2?44 (1?96) 11?02 (2?85) 5?66 (3?58) 9?48 (5?19) 16?97 (6?30) 23?79 (11?56) 32?47 (15?15)
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TABLE 3. Mean (SD) NHP scores for chronic bronchitis patients at non-AECB in the present study; in a previous study (COPD patientswith co-morbid conditions) (45); patientswith
benignprostatic hypertrophy (53); patientswith Parkinson’s disease (54); andhealthyelderlycontrols (54)
NHP domain Chronic bronchitis (n= 187) COPDwith co-morbidity
(n= 58) (45)
Benignprostatic hyper-
trophy (n= 350) (53)
Parkinson’s disease (n= 233)
(54)
Healthyelderlycontrols
(n= 100) (54)
Energy 42?5 (39?5) 39?1 (34?6) 23?2 (34) 26?3 (33?3) 10?0 (21?2)
Pain 9?8 (19?8) 15?4 (25?6) 9?3 (18) 22?0 (24?6) 13?5 (22?5)
Emotionalreactions 18?2 (23?7) 14?2 (19?5) 14?4 (21) 13?1 (17?0) 6?3 (13?5)
Sleep 25?5 (29?6) 21?2 (27?9) 26?2 (28) 27?2 (28?4) 19?4 (28?4)
Social isolation 11?0 (22?2) 7?1 (19?4) 7?6 (18) 20?4 (23?6) 10?8 (17?6)
Physicalmobility 18?5 (23?9) 17?1 (16?5) 9?9 (18) 41?2 (31?7) 11?1 (16?2)
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TABLE 4. Mean (SD) SGRQdomain scores at AECBintermsofthe socio-demographic, clinical, andrisk factorshavinga signi¢-
cant associationwith QoL
Factor SGRQSymptoms SGRQActivity SGRQE¡ects SGRQTotal
Age
o52 yrs 55?7 (19?6) 40?1 (26?8) 29?8 (20?8) 37?2 (19?6)
52^61yrs 66?9 (19?9) 55?9 (28?3) 42?1 (21?6) 50?4 (21?6)
62^71yrs 70?3 (18?6) 64?1 (23?0) 45?5 (20?8) 55?6 (19?0)
72 yrs 69?5 (18?2)** 69?5 (21?8)*** 45?5 (20?1)*** 57?0 (18?0)***
Employed
No 69?0 (19?4) 64?9 (26?5) 44?9 (21?0) 55?2 (19?3)
Yes 59?4 (18?9)*** 43?0 (29?0)*** 32?7 (20?7)*** 40?1 (20?5)***
Disability
No 64?3 (19?4) 55?5 (27?5) 39?0 (21?3) 48?4 (20?7)
Yes 77?3 (17?5)*** 76?6 (13?6)*** 55?0 (18?1)*** 65?3 (14?1)***
Air pollution (home)
No 66?5 (19?6) 59?2 (26?9) 40?9 (20?9) 50?9 (20?4)
Yes 64?2 (20?1) 53?0 (27?7) 43?8 (26?4) 49?9 (23?9)
Co-morbid disease
1 56?7 (38?2) 10?0 (19?7) 24?0 (25?7) 35?7 (31?5)
2 58?6 (39?6) 13?8 (22?1) 28?9 (29?3) 46?0 (35?7)
3 62?0 (35?9) 19?7 (25?5) 30?0 (28?0) 33?0 (34?5)
4^6 76?8 (31?8) 27?5 (31?7)*** 30?5 (27?1) 42?9 (32?5)
AECB number
0^1 54?4 (20?6) 47?1 (29?9) 31?2 (20?7) 40?1 (21?0)
2 62?0 (22?2) 59?0 (27?2) 38?8 (22?4) 48?6 (21?4)
3 67?2 (17?2) 59?1 (26?9) 41?8 (21?3) 51?6 (20?1)
4 72?3 (17?5) 59?3 (24?9) 43?7 (20?4) 53?6 (20?2)
5+ 74?2 (14?9)*** 64?2 (25?7) 49?9 (20?0)** 58?5 (18?6)**
Basic CB severity
Mild 52?2 (19?4) 40?7 (33?8) 30?5 (21?4) 37?9 (23?0)
Moderate 65?0 (18?1) 57?8 (25?3) 39?7 (20?3) 49?6 (19?1)
Severe 76?7 (16?9)*** 68?5 (22?3)*** 50?8 (21?0)*** 60?7 (18?7)***
AECBAnthonisen
Type1 71?1 (19?7) 63?5 (25?7) 45?5 (21?9) 55?7 (20?5)
Type 2 68?9 (17?6) 63?0 (24?8) 44?5 (22?1) 54?4 (20?0)
Type 3 57?8 (19?5)*** 48?4 (28?3)** 33?0 (19?2)** 41?6 (19?6)****Po0?05, **Po0?01, ***Po0?001.
46 RESPIRATORYMEDICINEthose aged72 years.These ¢gures were very similar in
the activity ande¡ects domains (data not shown).Unem-
ployed patients reported generally poorer QoL than
those employed at both AECB and non-AECB (Tables 4
and 5). This e¡ect was only partially explained by the
greater age of subjects not in employment.Thosewith a
disability reported signi¢cantly poorer QoL at both
assessments (Tables 4 and 5).
Risk factors
Scores on the SGRQ did not generally di¡er signi¢cantly
between current and non-smokers. In terms of air pollu-
tion at home, those reporting such pollution reported
signi¢cantly better QoL at non-AECB, but not AECB,
in all SGRQ domains (Table 5). This re£ected a signi¢-
cantly greater improvement in QoL from AECB to non-
AECB among these subjects [mean (SD) improvement intotal score14?9 (15?5) comparedwith 5?74 (19?5) in those
not reporting air pollution; Po0?05]. Similar e¡ects on
QoLwere observed in terms of patient reports of expo-
sure to air pollution at work (data not shown).The rela-
tionships between number of co-morbid diseases and
QoL were inconsistent, although QoL was generally
poorer with increasing number of co-morbid conditions
(Tables 4 and 5). AECBs were associated with a greater,
but non-signi¢cant, deterioration in QoL in those in the
two heavier BMI groups [mean (SD) deterioration in QoL
score 10?3 (16?8) in individuals with a BMI of 27 com-
paredwith 2?44 (21?1) in thosewith a BMI ofo24].
Clinical factors
The greater the number of acute exacerbations in the
year before the study the poorer the QoL at AECB
(Table 4). At non-AECB, however, the groups di¡ered
TABLE 5. Mean (SD) SGRQ domain scores at non-AECB in terms of the socio-demographic, clinical, and risk factors having a
signi¢cant associationwith QoL
Factor Symptoms Activity E¡ects Total
Age
o52 yrs 54?9 (17?4) 29?4 (24?0) 19?9 (17?1) 28?7 (16?6)
52^61yrs 62?8 (16?7) 45?1 (26?3) 31?1 (23?9) 40?6 (21?1)
62^71yrs 62?3 (20?3) 53?6 (24?4) 34?3 (20?4) 44?9 (19?4)
72 yrs 69?7 (19?6)*** 61?4 (25?5)*** 39?4 (20?7)*** 51?5 (19?2)***
Employed
No 64?2 (20?4) 55?1 (25?3) 35?3 (21?7) 46?4 (20?0)
Yes 58?9 (15?4)* 30?3 (25?3)*** 22?0 (19?0)*** 30?5 (18?5)***
Disability
No 61?4 (18?8) 44?8 (27?1) 29?1 (20?1) 39?4 (19?9)
Yes 68?8 (20?0)* 63?0 (23?4)** 41?7 (23?5)** 52?8 (19?0)**
Air pollution (home)
No 63?8 (18?9) 50?2 (27?6) 32?4 (21?6) 43?2 (20?6)
Yes 55?1 (19?8)* 32?2 (22?8)** 24?8 (22?2)* 32?0 (20?2)**
Co-morbid disease
1 56?1 (19?7) 39?7 (27?0) 25?9 (20?3) 35?3 (19?6)
2 68?0 (16?2) 51?9 (30?3) 36?3 (24?0) 46?3 (22?2)
3 61?8 (18?8) 52?8 (23?8) 31?7 (19?2) 43?3 (18?0)
4^6 75?8 (15?4)*** 66?1 (19?7)*** 46?9 (22?2)*** 57?6 (17?8)***
AECB number
0^1 60?8 (20?8) 53?0 (31?2) 35?8 (26?5) 45?9 (25?4)
2 58?1 (21?6) 42?5 (28?7) 26?0 (22?0) 36?5 (21?6)
3 57?9 (16?0) 48?7 (26?9) 30?9 (19?3) 40?6 (18?5)
4 63?9 (19?7) 45?2 (27?4) 31?8 (22?1) 41?4 (20?4)
5+ 70?3 (15?9)** 50?0 (25?5) 33?7 (20?3) 44?8 (19?3)
Basic CB severity
Mild 53?4 (14?1) 38?4 (25?2) 23?0 (17?2) 33?2 (16?8)
Moderate 60?1 (18?3) 42?3 (27?5) 28?4 (20?4) 37?8 (19?7)
Severe 72?0 (19?2)*** 62?4 (22?6)*** 40?5 (22?3)*** 52?7 (19?4)***
AECBAnthonisen
Type1 67?2 (16?6) 49?5 (27?8) 31?2 (22?6) 42?8 (21?3)
Type 2 65?2 (20?2) 51?0 (27?3) 34?8 (19?9) 45?0 (20?0)
Type 3 55?1 (18?8)** 41?8 (27?7) 26?0 (21?9)** 35?7 (20?6)***Po0?05, **Po0?01, ***Po0?001.
QUALITYOFLIFE INCHRONICBRONCHITIS 47only slightly (Table 5), this re£ecting the greater dete-
rioration in QoL at AECB in thosewith a larger number
of previous exacerbations [mean (SD) deterioration 13?3
(17?4) in those with ¢ve or more previous exacerbations
compared with a mean improvement of 11?9 (24?5) in
those with no or one previous exacerbation; Po0?01).
While QoL at both AECB and non-AECB deteriorated
with increasing severity of the CB (Tables 4 and 5), the
e¡ect of an AECB on QoL did not appear to depend on
the severityof theunderlying condition: the extentofde-
terioration in QoL at AECBwas not associatedwith CB
severity (data not shown).Moreover, therewas no statis-
tically signi¢cant interactionbetweenAECB severity and
CB severity. Nevertheless, the greater the severity of
the AECB, classi¢ed both by the physician (data not
shown) and according to Anthonisen criteria, the poorer
the QoL at AECB (Table 4). The greatest di¡erence in
QoL score, however, was between subjects with type 2and type 3 AECB grade; subjects with the most severe
type 1 AECBs reported QoL scores only slightly higher
than thosewith type 2 AECBs. Since subjects in theType
1group generally reported greater improvement in QoL
at non-AECB than subjectswith less severe AECBs (data
not shown), the relationships between Anthonisen
AECB type and QoL at non-AECB are generally not
linear, with the only consistent relationship being be-
tween Anthonisen AECB grade and SGRQ Symptom
score, which increased with increasing AECB severity
(Table 5). The greater deterioration in QoL at AECB in
those with increased AECB severity mirrors the rela-
tionships seenwith number of symptoms inwhich a line-
ar trend was evident, but which did not reach statistical
signi¢cance (data not shown).
There were no consistent relationships between
number of medications and QoL. In terms of the type of
medication, thosewhowere taking antibiotics or expec-
48 RESPIRATORYMEDICINEtorants at AECB both reported signi¢cantly greater im-
provement in QoL by the time of non-AECB (data not
shown).
Fitting ofmultiple regressionmodels
QoL at AECB
After adjusting for the severity of the basic condition,
the factors onmultiple regression analysis with themost
consistent individual independent relationships with
SGRQ QoL at AECB were age, employment status,
BMI, number of prior AECBs and Anthonisen grade of
AECB. The regression coe⁄cients (data not shown)
demonstrate that each year increase in age is associated
with a slight, although statistically signi¢cant, increase
(worsening) in e¡ects and total score. Females had, on
average, a 10-point better symptom score than males,
and those who were in employment reported between
7 and16-point average better scores in all domains than
those not. An increase of1BMI unit was associatedwith
3^5-point poorer activity, e¡ects and total domain
scores, ¢gures similar to the QoL decrease associated
with the number of prior AECBs and the Anthonisen
AECB grade.
Deterioration in QoL at AECB
After adjusting for the severity of the basic condition at
AECB, only two factors were consistently associated
with the deterioration in QoL at AECB relative to that
at non-AECB. These factors were the number of prior
AECBs during the previous12 months and the reporting
of air pollution at home at the time of the AECB. The
regression coe⁄cients associatedwith these factors are
positive and large, indicating a large e¡ect on QoL
deterioration: patients reporting air pollution at home
reported an average QoL deterioration of between11?6
and16?5 points in the four SGRQ domains; and each ad-
ditional AECB during the past year was associated with
an average QoL deterioration during the AECB of
around 6 in each SGRQ domain. In addition, patients
whowereunemployed andwhowereyounger had signif-
icantly greater deterioration in overall SGRQ symptom
scores but in no other SGRQ domain.
DISCUSSION
This cross-sectional study is based on data collected
from patients recruited by a randomly selected sample
of doctors.The HRQoL of half of these CB patients was
assessed at the time of an AECB and approximately
6 months later at a stable phase (non-AECB).This data,
although not collected prospectively from the time of
non-AECB, thus allows assessment of the e¡ect of an
AECB on QoL in CB patients. Strengths of the studyinclude: the sampling frameusedwhichprovided agener-
al population sample of patients with CB; the fact that
most of the recruited patients remained in the study;
the gathering of data on a wide variety of demographic,
risk, and clinical factors; and the use of a widely-used
generic (the NHP) and speci¢c (SGRQ) QoLmeasure.
Potential limitations of the study include: the low
investigator response rate, although any resultant bias
in patient recruitment is likely to be small; the collection
of QoL data on less than one half of the recruited
patients, although anybias is again likely to be small since
the selection process, even though in terms of the inves-
tigator rather than the patient, was random; the fact
that some data were collected as patient self-reports
and not independently veri¢ed; the subjective measure-
ment of CB and AECB severity, although AECBs were
alsomeasured objectively in terms of Anthonisen criter-
ia; and the prospective collection of data starting from
the point of an AECB rather than non-AECB.This latter
pointmeans that the di¡erence inQoL between the two
assessment points, referred to here most usually as the
deterioration in QoL associated with an AECB, is more
accurately the improvement in QoL following resolution
of an AECB. This di¡erence is likely, however, to be a
good estimate of the QoL deterioration associatedwith
an AECB. The lack of objective measurements of pul-
monary function, since such measures are not routinely
undertaken by general practitioners, has the conse-
quence that with the exception of Anthonisen AECB se-
verity there are no such measures with which to
compare QoL scores.
While many other questionnaires have been devel-
oped to measure the HRQoL in patients with CB, the
NHP and the SGRQ are among the measures most
widely used.The SGRQwas designed tomeasure the im-
pact of chest disease (asthma, CB and emphysema) on
daily life and well-being, and thus should provide a mea-
sure of HRQoL which is directly related to the e¡ects of
CB.The genericNHP has been shown to have acceptable
internal consistency and construct validity in patients
with asthma and COPD in general practice (45) and to
have abilities similar to the SF-36 in discriminating di¡er-
ent levels of respiratory impairment (55). In this regard,
the SF-36 hasbeen found to be a useful and validmeasure
ofHRQoL in patientswith chronic lungdisorders, includ-
ing CB, emphysema and asthma (56).
The data collected in this study suggest that the QoL
of CB patients, when compared to individuals in the gen-
eral population, is poor even at non-AECB.This e¡ect of
CB onQoLwas particularly evident in terms of theNHP
domains of energy, emotional reactions and sleep. In
terms of comparison with patients with other chronic
conditions,CB patients reported notably poorer energy
and slightly poorer emotional reaction scores, than both
Parkinson’s disease patients and those with benign pro-
static hypertrophy.
QUALITYOFLIFE INCHRONICBRONCHITIS 49Moreover, among the CB patients assessed in this
study, signi¢cantQoLdeteriorationwas reportedduring
anAECB.This deteriorationwas evident in terms ofboth
the SGRQ and the NHP, with patients reporting poorer
QoL at the time of the AECB than at non-AECB.While
the di¡erences in QoL scores at the two assessments
reached statistical signi¢cance for all NHP domains, the
symptom domain of the SGRQ did not reach statistical
signi¢cance. This re£ects the fact that the questions in
this domain relate to symptoms experienced over the
previous12 months and not to current symptoms.Thus,
this domain was not employed in a clinical trial of cipro-
£oxacin vs. standard antibiotic care in CB patients with
an initial as well as recurrent AECBs (38). Moreover, in
the present study the percentage deterioration in QoL
from non-AECB to AECB was greater in terms of the
NHP than in all domains of the SGRQ. Indeed, there is
little published information on the use of any outcome
measure, including the SGRQ, in the measurement of
QoL in acute exacerbations of CB, although a recent
study compared three generic outcomemeasures in the
assessment of QoL at AECB (57). The SGRQ and the
NHP data collected in this study will be further com-
pared in terms of their assessment of QoL at AECB in a
future report.
At both AECB and non-AECB, and in terms of demo-
graphic and potential risk factors, QoL was poorer
among older patients, thoseunemployed, and thosewith
a disability as a result of their CB.QoL also tended to de-
crease with increasing number of co-morbid diseases,
and at AECB QoL was poorer among those of higher
BMI.The lack of any marked di¡erence in QoL between
current smokers and non-smokers is no doubt at least a
partial re£ection of the fact that the question asks only
aboutcurrent smoking; thosepatientswhohave stopped
smoking, perhaps on accountof poorQoL andCB symp-
toms, will be classi¢ed as ‘non-smokers’.
In terms of clinical factors, the greater the reported
number of AECBs in the previous12 months the poorer
theQoL atAECB. Such an associationwas also foundin a
study of 84 chronic obstructive pulmonary disease
patients, in that those patients with the most frequent
exacerbations over the past year reported signi¢cantly
poorer SGRQ total and component scores (15). While
QoL at both AECB and non-AECB deteriorated with
increasing severity of the underlying condition, and the
greater the severity of the AECB (physician and Anthon-
sien classi¢ed) the poorer the QoL at AECB, the e¡ect
of an AECB onQoL did not appear to depend on the se-
verity of the underlying CB.
The deterioration in QoL from non-AECB to AECB
was found to be particularly marked among those
reporting atmospheric pollution at home and those
reporting a large number of exacerbations during the
previous year. These e¡ects were independent. While
both of these measures were patient self-reports, andimpracticable to verify given the nature of this study,
both measures have previously been found to be asso-
ciated with QoL. For example, an association between
respiratory symptoms and the presence of air pollution
has been observed in many other studies (4^7). It is also
well known that AECBs, aswell as beingwidely regarded
as being the greatest causative factor in CB progression
(14), have a cumulative e¡ect onQoL (15).These relation-
ships observed in this study in terms of both air pollution
and previous AECB number were apparent with all
SGRQ domains and were independent of the underlying
severity of CB. In terms of the number of AECBs, a linear
e¡ect was evident with increasing number of exacerba-
tions being associated with deteriorating QoL. This ef-
fect was present for all four domains of the SGRQ.
In addition, those who were unemployed and who
were younger reported greater deterioration in the
overall SGRQ symptom domain. This association be-
tween younger age and a greater QoL deterioration at
the time of AECB was also apparent with the other
SGRQ domains (although not reaching statistical signi¢-
cance in themultiple regressionmodels), and it supports
therecentreportof a greaterdegree of distress at AECB
being reported by younger patients than by older ones
(20).
The study data also highlights the importance of anti-
biotics and expectorants in improving the QoL of pa-
tients su¡ering from an AECB: the QoL of patients
taking these drugs improved signi¢cantly by the time of
non-AECB. The use of antibiotics in the treatment of
AECBs is controversial, however, particularly for mild
exacerbations (58).This isbecause,while antibiotic treat-
ment bene¢ts patients by eradicating bacteria and resol-
ving the in£ammatory response, super¢cial mucosal
infectionsmay resolve spontaneously (59).
In conclusion, this study highlights the detrimental ef-
fect of CB, and in particular AECB, on HRQoL. Dete-
rioration of QoL at AECB is most strongly associated
with reports of both increasing number of AECBs during
the previous year and the presence of atmospheric air
pollution. This is consistent with evidence of associaion
of CB with long-term exposure to tra⁄c emission and
otheroutdoorpollution (4^7).Moreover, theresults em-
phasize the importance of preventing AECBs since
AECBs appear, as observed elsewhere (15), to have a
cumulative e¡ect on QoL.
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